Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
41 Young Men Die in South Africa After Circumcision Initiation - 2‘Trip of suffering’: Gaza evacuee details 24-hour journey to South Africa
- 3The Latest: Fueling begins as NASA aims to send 1st crew to the moon in 53 years
- 4Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- 54 Family SUVs: Joining Solace and Style
- An Extended period of Voyaging Carefully: the World with Reason
- Tuesday, April 7. Russia’s War On Ukraine: News And Information From Ukraine
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- WHO suspends Gaza medical evacuations after contractor killed by Israeli troops
- French Senate debates social media ban for under-15s
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- Famous SUVs With Low Energy Utilization In 2024
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Child influencers helped power a booming industry. It's time for a reckoning.
